Monographie - Oxaliplatin

Son güncelleme :
19/11/2024

Oxaliplatin

Kimyasal yapı

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Axiplatin	Almanya
Bendaplatin	Almanya
Bioezulen	Brezilya
Celdach	Peru
Crisapla	Ekvador, Şili, Venezuela
Crisatinox	Türkiye
Dabenzol	Arjantin, Ekvador
Dacplat	Arjantin
Eloxarin	Ekvador
Eloxatin	Amerika Birleşik Devletleri, Avusturya, Belçika, Birleşik Arap Emirlikleri, Brezilya, Büyük Britanya, İran, İspanya, İsveç, İsviçre, İtalya, Kolombiya, Lüksemburg, Malezya, Meksika, Mısır, Norveç, Peru, Portekiz, Romanya, Şili, Tayland, Türkiye, Venezuela, yeni Zelanda
Eloxatine	Fas, Fransa, İsviçre
Entia	Kolombiya, Meksika
Euroxaliplatine	Almanya
Glenoxal	Peru
Goxyral	Arjantin, Ekvador
Kebir	Arjantin, Peru
Linoxa	Türkiye
Lisix	Şili
Metaplatin	Arjantin
Oliptino	Arjantin
Onicol	Peru, Şili
Oxalibbs	Brezilya
Oxaliplan	Almanya
Riboxatin	Almanya

Kaynaklar : Oxaliplatin

	tip	yayın
1662	Dergi	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1950	Dergi	Trissel LA, Yanping Z. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration. J Oncol Pharm Practice 2004 ; 10: 191-195.
2207	Dergi	André A, Cisternino S, Roy A.L, Chiadmi F, Schlatter J, Agranat P, Fain O, Fontan J.E. Stability of oxaliplatin in infusion bags containing 5% dextrose injection. Am J Health-Syst Pharm 2007 ; 64, 18: 1950-1954.
2239	Dergi	Wang C, Zhang X, Liu HY. Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry. Chinese J New Drugs 2005 ; 14, 2: 189-191.
2253	Dergi	Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S. Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Rad 2001 ; 8: 716-718.
2258	Laboratuar	Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution. Ebewe Pharma 2007
2259	Laboratuar	Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions. Ebewe Pharma 2007
2321	Dergi	Junker A, Roy S, Desroches M.C, Moussay C, Berhoune M, Bellanger A, Fernandez C,Farinotti R. Stability of Oxaliplatin Solution. Ann Pharmacotherapy 2009 ; 43,2: 390-391.
2791	Dergi	Mehta A.M,.Van den Hoven J.M, Rosing H,.Hillebrand M.J.X, Nuijen B,. Huitema A.D.R, Beijnen J.H,.Verwaal V.J. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm 2015 ; 479 : 23-27.
2883	Dergi	Eiden C, Philibert L, Bekhtari K, Poujol S, Malosse F, Fr?d?ric Pinguet F. Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags. Am J Health-Syst Pharm 2009 ; 66, 21: 1929-1933.
3369	Laboratuar	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3413	Dergi	Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004 ; 21, 5: 891-894.
3602	Laboratuar	Mesna (Uromitexan®)- Summary of Product Characteristics Baxter SAS 2013
3634	Laboratuar	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3670	Dergi	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3706	Dergi	Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B. Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia. Farm Hosp 2014 ;38, 3:154-161
4004	Dergi	Krämer I, Sarakbi I, Thiesen J, Mainz. Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln. Krankenhauspharmazie 2017 ;38,7:334?340.

Mentions Légales